首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 分子標靶治療學 > Kinase的醫藥品開發與治療
產業/市場分類
生物科技 (1466)
分子標靶治療學 (51)
生技設備 (319)
生物材料 (55)
生物標記 (156)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (100)
市場調查報告書

Kinase的醫藥品開發與治療

Kinase Therapeutics:A Wealth of Targets Sparks a Highly Active Market

出版商 Insight Pharma Reports
出版日期 2006年05月 商品編碼 40180
內容資訊 英文 125 pages
價格
US $ 2750 Hard Copy
US $ 3500 PDF by E-mail (Single Site License) & Hard Copy


Kinase的醫藥品開發與治療 是由出版商Insight Pharma Reports在2006年05月所出版的。 這份英文市場調查報告書包含125 pages 價格從美金2750起跳。

簡介

Kinase的普遍性意指將Kinase使用在如糖尿病炎症性疾病及癌症等人體疾病的治療上

專注調查遺傳基因領域,並在全球擁有高度評價的美國市調公司 Insight Pharma Reports (總公司:Massachusetts state),詳盡地調查與分析Kinase的醫藥品開發活動,並出版綜合報告書"Kinase Therapeutics:A Wealth of Targets Sparks a Highly Active Market"

此報告書在下面的內容裡,除了說明疾病治療的有潛力新興研究與Kinase調節的目標相關性與特異性的確保、抗性的克服,也探討醫藥品反應最大化的臨床實驗設計、因應新治療所需的高額成本之道等的課題。

第1章 背景及科學概要:Kinase為重要的細胞內單一傳達酵素

  • Kinase的功能
  • Kinase的分類
  • Kinase:偏頗的藥劑目標
    • 癌症的現有相關性
    • Receptor Tyrosine Kinase
    • Non-receptor Tyrosine Kinase的目標
    • 癌治療用Serine-Threonine Kinase的目標
    • 癌以外疾病治療用Serine-Threonine Kinase的目標
  • 領域概要

第2章 開發中的Kinase抑制劑:大量目標的使用

  • Kinase抑制劑的種類:小分子與其替代
  • Receptor Tyrosine Kinase抑制劑
  • Non-receptor Tyrosine Kinase抑制劑
  • 癌治療用Serine-Threonine Kinase抑制劑
  • 癌以外疾病治療用Serine-Threonine Kinase抑制劑

第3章 產業/策略性展望:Kinase目標藥劑的市場機會

  • Kinase調節物質開發的特定課題
    • 目標的關連性與特異性
    • 抗性
    • 臨床設計
    • 成本
  • Kinase系列藥劑的市場
    • 癌症
    • 老年黃斑病變
    • 免疫/炎症性疾病
    • 糖尿病併發症

第4章 專家的解說

第5章 企業檔案

附錄

目錄

Abstract

Kinase Therapeutics: A Wealth of Targets Sparks a Highly Active Market reviews the considerable array of drug development efforts directed at kinases. This new CHA Advances report describes the various classes of kinases for which inhibitors are being developed, and examines the general strategies and technologies being employed to commercialize kinase inhibitors, including those underway at major pharmaceutical companies.

The ubiquity of kinases as potential targets means that eventually they will be exploited for virtually every human disease, particularly diabetes, inflammatory disorders, and especially cancer. The success of Novartis' Gleevec and Roche's Herceptin has demonstrated that kinase inhibitors for cancer that are effective and well-tolerated can enjoy strong sales.

Kinase modulation is without doubt a novel and promising approach to treating disease, but challenges remain. Those evaluated in the report include:

  • Ensuring target relevance and specificity.
  • Overcoming resistance.
  • Designing clinical trials to maximize the response to a drug.
  • Addressing the high cost of novel therapeutics.

Kinase Therapeutics: A Wealth of Targets Sparks a Highly Active Market evaluates the market potential for kinase-targeting compounds in development for a variety of diseases. Only those conditions for which drug candidates have reached at least mid-stage clinical development are covered. The report addresses the major disease categories, including:

  • Patient numbers for diseases of interest to developers of kinase modulators.
  • Competing therapeutics already on the market, particularly those that have recently gained regulatory approval.
  • Evaluation of the pros and cons of various targets and therapeutic approaches
  • Estimates of market sizes in dollars, where available.

Kinases represent perhaps the largest druggable class of targets. And yet researchers have only started to scratch the surface. Most, if not all, big pharmas have programs in this area, and are in fact among the leaders in the field. This report is crucial reading for executives who need to stay on top of the technical and commercial developments in the area of kinase therapeutics.

About the Author

Mark C. Via, an editor at CTB International Publishing, has ten years' experience writing and editing for pharmaceutical trade publications. Mr. Via holds a B.A. degree in history from Williams College. Mr. Via has authored previous Advances reports, including Inflammatory Disease Therapeutics: Pipelines and Competitive Dynamics.

Table of Contents

Chapter 1. Background and Scientific Overview:

Kinases Are Important Cellular Signaling Enzymes

  • 1.1 The Function of Kinases
  • 1.2 Classifying Kinases
  • 1.3 Kinases: Ubiquitous Drug Targets
  • The Established Link to Cancer
  • Targeting Receptor Tyrosine Kinases
  • Targeting Non-receptor Tyrosine Kinases
  • Targeting Serine-Threonine Kinases for Cancer
  • Targeting Serine-Threonine Kinases for Diseases Other than Cancer
  • 1.4 Overview of the Field

Chapter 2. Kinase Inhibitors in Development:

Tapping into a Wealth of Targets

  • 2.1 Types of Kinase Inhibitors: Small Molecules and Their Alternatives
  • 2.2 Receptor Tyrosine Kinase Inhibitors
    • EGFR Family
    • Split Kinase Domain Family
    • Targeting VEGF with RNAi for Opthalmic Diseases
  • 2.3 Non-receptor Tyrosine Kinase Inhibitors
    • Abl
    • Tec Family Kinases
    • Syk
    • JAK
  • 2.4 Serine-Threonine Kinase Inhibitors for Cancer
    • Ras-Raf-MEK-ERK Pathway
    • ALK5
    • PKC-α
    • PKC-β
    • ROCK
    • PI3 Kinase Pathway
    • mTOR
    • CDK
    • Aurora
    • PLK
    • CHK
  • 2.5 Serine-Threonine Kinase Inhibitors for Diseases Other than Cancer
    • PKC-δ
    • p38 MAP Kinase
    • JNK
    • MLK
    • NF-κB Pathway
    • PI3 Pathway
    • GSK3
    • mTOR
    • AMPK
    • PDHK

Chapter 3. Business and Strategic Outlook:

Market Potential for Kinase-Targeted Drugs

  • 3.1 Special Challenges in Developing Kinase Modulators
    • Target Relevance and Specificity
    • Resistance
    • Trial Design
    • Cost
  • 3.2 Markets for Kinase-Based Drugs
    • Cancer
    • Age-Related Macular Degeneration
    • Immune and Inflammatory Diseases
    • Diabetic Complications

Chapter 4. Expert Commentaries

  • 4.1 Shripad Bhagwat, PhD, SVP, Drug Discovery, Ambit Biosciences
  • 4.2 Sean G. Buchanan, PhD, Senior Director, Biology, SGX Pharmaceuticals
  • 4.3 K. Peter Hirth, Phd, CEO, Plexxikon
  • 4.4 Tony Hunter, PhD, Professor, Salk Institute for Biological Studies
  • 4.5 Michael Melnick, VP, Business and Corporate Development, Cell Signaling Technology

Chapter 5. Company Profiles

  • 5.1. Ambit Biosciences
  • 5.2. Amgen
  • 5.3. Amphora Discovery
  • 5.4. ARIAD Pharmaceuticals
  • 5.5. Astex Therapeutics
  • 5.6. AstraZeneca
  • 5.7. BioFocus
  • 5.8. Bristol-Myers Squibb
  • 5.9. Cell Signaling Technology
  • 5.10 CGI Pharmaceuticals
  • 5.11 Cyclacel Pharmaceuticals
  • 5.12. Eli Lilly & Co.
  • 5.13. Exelixis
  • 5.14. Millennium Pharmaceuticals
  • 5.15. Novartis
  • 5.16. Pfizer
  • 5.17. Rigel Pharmaceuticals
  • 5.18. Sanofi-Aventis
  • 5.19. Semafore Pharmaceuticals
  • 5.20. SGX Pharmaceuticals
  • 5.21. Sunesis Pharmaceuticals
  • 5.22. Upstate
  • 5.23. Vertex Pharmaceuticals

Appendix: Kinase Names

Company Index with Web Addresses

Back to Top